Enabling topical immunization via microporation: A novel method for pain-free and needle-free delivery of adenovirus-based vaccines

Gene Therapy

Volumn 10, Issue 3, 2003, Pages 251-260

  Bramson, J ^a   Dayball, K ^a   Evelegh, C ^a   Wan, Y H ^a   Page, D ^b   Smith, A ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b ELAN PHARMACEUTICALS   (United States)

^c Altea Genomics Inc   (United States)

Author keywords

Genetic vaccine; Skin; Topical immunization

Indexed keywords

ADENOVIRUS VECTOR; MELANOMA ANTIGEN; VIRUS VACCINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; CANCER IMMUNIZATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; EPIDERMIS; GENE EXPRESSION; HAIR FOLLICLE; HUMORAL IMMUNITY; INJECTION PAIN; MELANOMA; MOUSE; NEEDLE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; REPORTER GENE; REVIEW; SKIN CANCER; STRATUM CORNEUM; VAPORIZATION; VIRAL GENE DELIVERY SYSTEM; VITILIGO;

ADENOVIRIDAE; ADMINISTRATION, CUTANEOUS; ANIMALS; CANCER VACCINES; ELECTROPORATION; EPIDERMIS; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; INTRAMOLECULAR OXIDOREDUCTASES; MELANOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; SKIN; SKIN ABSORPTION; SKIN NEOPLASMS; VITILIGO;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES; MUS MUSCULUS;

EID: 0037322494     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301886     Document Type: Review

References (31)

1. Spellberg B. The cutaneous citadel: a holistic view of skin and immunity. Life Sci 2000; 67: 477-502.
2. Wan Y et al. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum Gene Ther 1997; 8: 1355-1363.
3. Perricone MA et al. Immunogene therapy for murine melanoma using recombinant adenoviral vectors expressing melanoma-associated antigens. Mol Ther 2000; 1: 275-284.
4. Forg P, von Hoegen P, Dalemans W, Schirrmacher V. Superiority of the ear pinna over muscle tissue as site for DNA vaccination. Gene Ther 1998; 5: 789-797.
5. Smith A et al. Fluorescein kinetics in interstitial fluid harvested from diabetic skin during fluorescein angiography: implications for glucose monitoring. Diabetes Technol Therapeutics 1999; 1: 21-27.
6. Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 2001; 14: 101-114.
7. McAllister DV, Allen MG, Prausnitz MR. Microfabricated microneedles for gene and drug delivery. Ann Rev Biomed Eng 2000; 2: 289-313.
8. Chen D et al. Epidermal immunization by a needle-free powder delivery technology: immunogenicity of influenza vaccine and protection in mice. Nat Med 2000; 6: 1187-1190.
9. Haensler J et al. Intradermal DNA immunization by using jet-injectors in mice and monkeys. Vaccine 1999; 17: 628-638.
10. Misra A, Ganga S, Upadhyay P. Needle-free, non-adjuvanted skin immunization by electroporation-enhanced transdermal delivery of diphtheria toxoid and a candidate peptide vaccine against hepatitis B virus. Vaccine 1999; 18: 517-523.
11. Wan Y et al. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines. Cancer Res 2000; 60: 3247-3253.
12. Hitt MM, Addison CL, Graham FL. Human adenovirus vectors for gene transfer into mammalian cells. Adv Pharmacol 1997; 40: 137-206.
13. Fan H, Lin Q, Morrissey GR, Khavari PA. Immunization via hair follicles by topical application of naked DNA to normal skin. Nat Biotechnol 1999; 17: 870-872.
14. Tang DC, Shi Z, Curiel DT. Vaccination onto bare skin. Nature 1997; 388: 729-730.
15. Shi Z et al. Protection against tetanus by needle-free inoculation of adenovirus- vectored nasal and epicutaneous vaccines. J Virol 2001; 75: 11 474-11 482.
16. Banga AK. Electrically Assisted Transdermal and Topical Drug Delivery. Taylor & Francis: London, 1998.
17. Bramson JL, Wan YH. The efficacy of genetic vaccination is dependent upon the nature of the vector system and antigen. Expert Opin Biol Ther 2002; 2: 75-85.
18. Steitz J et al. Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma. Int J Cancer 2000; 86: 89-94.
19. Bowne WB et al. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med 1999; 190: 1717-1722.
20. Steitz J, Bruck J, Knop J, Tuting T. Adenovirus-transduced dendritic cells stimulate cellular immunity to melanoma via a CD4(+) T cell-dependent mechanism. Gene Ther 2001; 8: 1255-1263.
21. Overwijk WW et al. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci USA 1999; 96: 2982-2987.
22. Pardoll DM. Inducing autoimmune disease to treat cancer. Proc Natl Acad Sci USA 1999; 96: 5340-5342.
23. Chen PW et al. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J Immunol 1996; 156: 224-231.
24. Zhai Y et al. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J Immunol 1996; 156: 700-710.
25. Hirschowitz EA et al. Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma. Gene Ther 1998; 5: 975-983.
26. Glenn GM et al. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med 2000; 6: 1403-1406.
27. Glenn GM, Rao M, Matyas GR, Alving CR. Skin immunization made possible by cholera toxin. Nature 1998; 391: 851.
28. Chen D et al. Epidermal powder immunization induces both cytotoxic T-lymphocyte and antibody responses to protein antigens of influenza and hepatitis B viruses. J Virol 2001; 75: 11 630-11 640.
29. Ng P et al. An enhanced system for construction of adenoviral vectors by the two-plasmid rescue method. Hum Gene Ther 2000; 11: 693-699.
30. Bramson J et al. Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12. Hum Gene Ther 1996; 7: 333-342.
31. Bramson JL, Hitt M, Gauldie J, Graham FL. Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Ther 1997; 4: 1069-1076.